A phase I study of paclitaxel in combination with etoposide in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) (Q74284448)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9493138%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

title

A phase I study of paclitaxel in combination with etoposide in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9493138%20AND%20SRC:MED&resulttype=core&format=json

non-small-cell lung carcinoma

9 November 2019

main subject

1 reference

1 reference

1 reference

D Ukena

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9493138%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

M Berg

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9493138%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

M Leutz

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9493138%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

L Zell

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9493138%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

P Schlimmer

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9493138%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

G W Sybrecht

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9493138%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

publication date

1 January 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9493138%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9493138%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9493138%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9493138%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

page(s)

31-36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9493138%20AND%20SRC:MED&resulttype=core&format=json

Polychemotherapy in advanced non small cell lung cancer: a meta-analysis

9 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900071-8

7 January 2021

Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900071-8

7 January 2021

Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900071-8

7 January 2021

Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900071-8

7 January 2021

Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900071-8

7 January 2021

Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900071-8

7 January 2021

Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900071-8

7 January 2021

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900071-8

7 January 2021

Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900071-8

7 January 2021

Taxol produces a predominantly sensory neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900071-8

7 January 2021

A phase I trial of taxol given by a 6-hour intravenous infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900071-8

7 January 2021

Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900071-8

7 January 2021

Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900071-8

7 January 2021

Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900071-8

7 January 2021

10.1016/S0169-5002(97)00071-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9493138%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference